Acquisition includes HS235, a potentially best-in-class activin signalling inhibitor in clinical development for treatment of cardiopulmonary diseases HS235 offers potential to treat pulmonary ...
Chinese drugmaker Jiangsu Hengrui Pharmaceuticals has agreed to develop up to 12 of its drugs with British pharmaceutical giant GSK. Hengrui Pharma granted GSK an exclusive worldwide licence to its ...
GSK is sourcing early-stage science across a wide range of technologies and disease areas, while placing more selective bets ...
Selected a potential first-in-class Pol Theta Helicase development candidate in collaboration with GSK Observed complete responses in preclinical combination studies of Pol Theta Helicase DC with ...
SAN MATEO, Calif., Jan. 7, 2026 /PRNewswire/ -- Helix, the leading enterprise genomics company, today announced a multi-year strategic collaboration with GSK, the global biopharma company. This ...
GSK Plc’s new chief executive officer plans to speed up research and development and look for acquisitions as the British drugmaker tries to convince investors it can offset a looming patent cliff.
HS235 offers potential to treat pulmonary hypertension (PH) patients while reducing the risk of bleeding and providing unique metabolic benefits compared to existing therapies MONTREAL, Feb. 25, 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results